Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin

Drug Development Research

Volumn 37, Issue 4, 1996, Pages 231-248

  Young, Andrew A ^a   Vine, William ^a   Gedulin, Bronislava R ^a   Pittner, Richard ^a   Janes, Susan ^a   Gaeta, Laura S L ^a   Percy, Amy ^a   Moore, Candace X ^a   Koda, Joy E ^a   Rink, Timothy J ^a   Beaumont, Kevin ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Gastric emptying; Pharmacodynamics; Pharmacokinetics; Rats

Indexed keywords

AMYLIN; GLUCOSE; LACTIC ACID; PRAMLINTIDE;

ANIMAL CELL; ARTICLE; CALCIUM BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LACTATE BLOOD LEVEL; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RECEPTOR AFFINITY; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION;

EID: 8944258562     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M     Document Type: Article

References (41)

1. Aiyar N, Baker E, Martin J, Patel A, Barone F, Stadel J, Willette R (1994): Distinct binding sites for calcitonin gene-related peptide (CGRP) and amylin in the porcine nucleus accumbens. FASEB 8:A832.
2. Aiyar N, Baker E, Martin J, Patel A, Stadel JM, Willette RN, Barone FC (1995): Differential calcitonin gene-related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: Potential models for studying CGRP/amylin receptor subtypes. J Neurochem 65:1131-1138.
3. + transport in rat soleus muscle. Am J Physiol 264:C419-C429.
4. Beaumont K, Kenney MA, Young AA, Rink TJ (1993): High affinity amylin binding sites in rat brain. Mol Pharmacol 44:493-497.
5. Betsholtz C, Svensson V, Rorsman F, Engstrom U, Westermark GT, Wilander E, Johnson K, Westermark P (1989): Islet amyloid polypeptide (IAPP)-cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res 183:484-493.
6. Brain SD, Wimalawansa S, MacIntyre I, Williams TJ (1990): The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit. Am J Pathol 136:487-490.
7. Brown K, Menius A, Sandefer E, Edwards J, James M (1994): The effects of amylin on changes in plasma glucose and gastric emptying following an oral glucose load in conscious dogs. Diabetes 43:172A.
8. Castillo MJ, Scheen AJ, Lefebvre PJ (1995): Amylin islet amyloid polypeptide: Biochemistry, physiology, patho-physiology. Diabetes Metab 21:3-25.
9. + and glucose transport in soleus muscle. Am J Physiol 252:E492-E499.
10. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987): Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632.
11. Cooper GJS, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, Rothbard JB, Willis AC, Reid KB (1988): Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 85:7763-7766.
12. Dégano P, Silvestre RA, Salas M, Peiro E, Marco J (1993): Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner - study in the perfused rat pancreas. Regul Pept 43:91-96.
13. Findlay DM, Michelangeli VP, Eisman JA, Frampton RJ, Moseley JM, MacIntyre I, Whitehead R, Martin TJ (1980): Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines. Cancer Res 40:4764-4767.
14. Hunter WM (1967): The preparation of radioiodinated proteins of high activity, their reaction with antibody in vitro: The radioimmunoassay. In Weir DM (eds): Handbook of Experimental Immunology. Philadelphia: FA Davis,
15. Hunter WM, Greenwood FC (1962): Preparation of Iodine-131 labelled human growth hormone of high specific activity. Nature 194:495-496.
16. Janes SM, Albrecht E, Beaumont K, Beeley NRA, Gaeta LSL, Johnston PD, Jones H, Moore CX, Pittner RA, Rink TJ, Young AA (1996): Pramlintide: An analogue of human amylin with improved physicochemical properties suitable for clinical development in diabetes. Pharmaceutical Research (submitted).
17. Kolterman OG, Gottlieb AB, Moyses CJ (1994a): Administration of tripro-amylin reduces postprandial hyperglycemia in subjects with juvenile-onset diabetes. Diabetologia 37:A72.
18. Kolterman O, Gottlieb A, Moyses C (1994b): Amylin agonist, AC137, reduces postprandial hyperglycemia in subjects with insulin dependent diabetes mellitus (IDDM). Diabetes 43:78A.
19. Kolterman O, Kisicki JC, Peltier L, Gottlieb A, Moyses C (1994c): Infusion of amylin agonist AC-0137 reduces postprandial hyperglycemia in subjects with type 1 diabetes. Clin Res 42:87A.
20. Kolterman OG, Gottlieb AB, Organ KA, Thompson RG (1995a): Reduction of postprandial hyperglycemia in patients with type II diabetes by the human amylin analogue AC137. Diabetologia 38:A193.
21. Kolterman OG, Gottlieb A, Moyses C, Colburn W (1995b): Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 18:1179-1182.
22. Kolterman O, Organ K, Gottlieb A (1995c): Intravenous infusion of the human amylin analogue, AC 137, reduces postprandial hyperglycemia in subjects with type I diabetes mellitus receiving oral nutrients but not IV glucose. Diabetes 44:127A.
23. Kolterman O, Peterson J, Gottlieb A (1995d): Subcutaneous administration of AC137, a human amylin analogue, reduces postprandial hyperglycemia in subjects with type I diabetes mellitus. Diabetes 44:57A.
24. Leighton B, Cooper GJS (1988): Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335:632-635.
25. Macdonald I, King P, Kong M, Stubbs T, Perkins A, Moyses C, Tattersall R (1995): Infusion of the human amylin analogue, AC137, delays gastric emptying in men with IDDM. Diabetologia 38:A32.
26. Morley JE, Flood JF (1991): Amylin decreases food intake in mice. Peptides 12:865-869.
27. Muff R, Stangl D, Born W, Fischer JA (1992): Comparison of a calcitonin gene-related peptide receptor in a human neuroblastoma cell line (SK-N-MC) and a calcitonin receptor in a human breast carcinoma cell line (T47D). Ann N Y Acad Sci 657:106-116.
28. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL (1990): Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 85:973-976.
29. Phelps JL, Blase E, Koda JE (1996): Development and characterization of monoclonal antibodies specific for amylin. Hybridoma (submitted).
30. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K (1994): In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62:553-567.
31. Thompson RG, Gottlieb AB, Organ K, Kolterman OG (1995): The human amylin analogue (AC137) reduces glucose following Sustacal in patients with type II diabetes. Diabetes 44:127A.
32. Van Rossum D, Menard DP, Fournier A, St Pierre S, Quirion R (1994): Autoradiographic distribution and receptor binding profile of [I-125]Bolton Hunter-rat amylin binding sites in the rat brain. J Pharmacol Exp Ther 270:779-787.
33. Westfall TC, Curfman-Falvey M (1995): Amylin-induced relaxation of the perfused mesenteric arterial bed: Meditation by calcitonin gene-related peptide receptors. J Cardiovasc Pharmacol 26:932-936.
34. Young AA (1993): Amylin and its effects on the Con cycle. Taking Control in Diabetes: a workshop held during the meeting of the European Association for the Study of Diabetes, Prague, September 1992, Surrey, UK: Synergy Medical Education, pp 16-20.
35. Young AA, Wang MW, Cooper GJS (1991): Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 291:101-104.
36. Young AA, Gedulin B, Wolfe-Lopez D, Greene HE, Rink TJ, Cooper GJS (1992): Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists. Am J Physiol 263:E274-81.
37. Young AA, Rink TJ, Wang MW (1993): Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP-alpha) in the fasted, anaesthetized rat. Life Sci 52:1717-1726.
38. Young AA, Gedulin B, Vine W, Percy A, Rink TJ (1995a): Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648.
39. Young AA, Jodka CM, Green DE, Gedulin BR (1995b): Inhibition of arginine-induced glucagon secretion by amylin in rats. Diabetes 44:238A.
40. Young A, Pittner R, Gedulin B, Vine W, Rink T (1995c): Amylin regulation of carbohydrate metabolism. Biochem Soc Trans 23: 325-331.
41. Zaidi M, Datta HK, Bevis PJR, Wimalawansa SJ, Macintyre I (1990): Amylin-amide: A new bone-conserving peptide from the pancreas. Exp Physiol 75:529-536.